This is the authors' abstract. We don't add key points for this paper.
The first chimeric antigen receptor T-cell therapy, tisagenlecleucel, received FDA approval for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia who haven't responded to standard therapy or who have relapsed at least twice.
Answers are grounded in this paper and cite their sources.
No takes yet. Share an insight, caveat, or question.
A 2017 study studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: